Key result
Postoperative oral dabigatran after hip arthroplasty was associated with significantly higher wound discharge after 5 days compared to dalteparin (32% vs 10%; P=0.003).
Why the study?
Does oral dabigatran increase wound discharge compared to dalteparin in patients undergoing hip arthroplasty?
Cohort (n=123)
Does oral dabigatran increase wound discharge compared to dalteparin in patients undergoing hip arthroplasty?
Absolute Event Rate: 32% vs 10%
p-value: p=0.003
Dabigatran use for thromboprophylaxis after hip arthroplasty is associated with significantly higher rates of wound discharge and delayed hospital discharge compared to dalteparin.
No takes yet. Share an insight, caveat, or question.
May favor dalteparin over dabigatran to reduce wound discharge after hip arthroplasty; leaves open need for RCT confirmation.
Gill et al. (2011) conducted a cohort in Hip arthroplasty (n=123). Oral dabigatran vs. Subcutaneous dalteparin was evaluated on Wound discharge after 5 days (p=0.003). Postoperative oral dabigatran after hip arthroplasty was associated with significantly higher wound discharge after 5 days compared to dalteparin (32% vs 10%; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: